MIT researchers have developed a new type of spring-like device that uses a flexible element to help power biohybrid robots, reports Brian Heater for TechCrunch. “The muscle fiber/flexure system can be applied to various kinds of robots in different sizes,” Heater writes, adding that the researchers are, “focused on creating extremely small robots that could one day operate inside the body to perform minimally invasive procedures.”
Prof. Xuanhe Zhao speaks with Amerigo Allegretto of AuntMinnie.com about his work developing a new ultrasound sticker that can measure the stiffness of internal organs and could one day be used for early detection and diagnosis of disease. “Due to the huge potential of measuring the rigidity of deep internal organs, we believe we can use this to monitor organ health,” Zhao explains.
Prof. Ron Weiss co-founded Strand Therapeutics, a biotech company developing mRNA therapies, reports Emily Mullin for Wired. “The notion is that genetic circuits can really have significant impact on safety and efficacy,” says Weiss. “This begins to really open up the door for creating therapies whose sophistication can match the underlying complexity of biology.”
Scientific American reporter Payal Dhar spotlights how MIT engineers developed a beating, biorobotic replica of the human heart that could be used to “simulate the workings of both a healthy organ and a diseased one.” The replica, "which pumps a clear fluid instead of blood, is hooked up to instruments that measure blood flow, blood pressure, and more," writes Dhar. "It’s also customizable: the user can change the heart rate, blood pressure and other parameters, then watch how these changes affect the heart’s function in real time.”
Researchers from MIT have developed, “nanoelectronics they hope can one day enter the brain and treat conditions like Alzheimer’s by monitoring some of these brain patterns,” reports Elizabeth Hlavinka for Salon. “Their device, which they call Cell Rover, serves as a sort of antenna that can help external devices monitor cells.”
Prof. Ritu Raman has developed centimeter-scale robots that use biological muscle, reports Liam Drew for Nature. “Raman is now developing muscle systems connected to neurons that can trigger contraction, just as they exist in animals,” writes Drew. “In the longer term, she aims to use networks of biological neurons that can sense external stimuli as well, enabling them to move in response to environmental cues.”
Jasmina Aganovic '09 speaks with MSNBC reporter Daniela Pierre-Bravo about her mission to transform the beauty industry by creating more sustainable products through her startup Arcaea. “The way that I’ve always viewed this industry is that it touches almost every single human being on this planet every single day,” says Aganovic. The beauty industry also, “plays such an important emotional role in our day-to-day lives in terms of self-expression and self-care, the ability to escape when things are a little bit tough, those like little small indulgences.”
Ginkgo Bioworks, a biotech company founded by Jason Kelly BS ’03, PhD ’08, Reshma Shetty PhD ‘08, Barry Canton PhD ’08, Austin Che PhD ’08 and Professor Tom Knight, is working to develop synthetic fragrances, reports Scott Kirsner for The Boston Globe.
Researchers at the McGovern and Broad Institutes have developed a bacterial "nanosyringe" that can inject large proteins into specific cells in the body, which could lead to safer and more effective treatments for a variety of conditions, including cancer, reports Michael Le Page for New Scientist. “The fact that this can load a diversity of different payloads of different sizes makes it unique amongst protein delivery devices,” says graduate student Joseph Kreitz.
Ingrid Wickelgren at Scientific American highlights a new study from researchers at the McGovern and Broad Institutes, in which they used a bacterial ‘nanosyringe’ to inject large proteins into human cells. “The syringe technology also holds promise for treating cancer because it can be engineered to attach to receptors on certain cancer cells,” writes Wickelgren.
Prof. Ritu Raman speaks with Scientific American about her work “building machines that we call bio-hybrid because they're part biological and part made out of synthetic materials. The biological robots that we're building are powered by muscle tissue so that every time the muscle contracts, you could get something that looks like movement.”
Boston Globe reporter Ryan Cross spotlights Chroma Medicine, a biotech startup co-founded by MIT researchers that is “developing a new class of gene editing technologies that could control how our genetic code is read without changing the code itself.” Cross explains that Chroma Medicine’s technology could “have broad applications for treating both rare and common diseases.”
Deepak Dugar MBA ’13, PhD ’13 founded Visolis, a biomanufacturing company developing carbon-negative, high-performance materials, reports John Cumbers for Forbes. “We use biology to make platform molecules. And then we use chemistry to turn them into a lot of different products. Because of this unique combination, we have an advantage both in terms of market as well as cost of technology development,” says Dugar.
Asimov - an MIT spinout co-founded by Prof. Christopher Voigt, Alec Nielsen PhD ’16, Raja Srinivas PhD ’16, and Boston University Prof. Douglas Densmore - is a biotechnology company developing tools to design living systems, reports John Cumbers for Forbes. “Every cell is capable of computing. Perceiving environmental signals, information processing, turning genes on and off,” says Nielsen. “The ability to engineer this gift of evolution is, in my view, going to be the most meaningful and impactful technology that humans have ever developed.”
Harry McNamara PhD ’19, David Heller ’18, and Shara Ticku co-founded C16 Biosciences, a biotechnology company that uses synthetic biology to address environmental concerns, reports John Cumbers for Forbes. The company “wants to replace conflict palm oil with a sustainable alternative made in yeast using precision fermentation,” writes Cumbers.